ArticleCancer causes & control : CCC2026
Geospatial heterogeneity of hotspots for incidence and late-stage diagnosis of breast, colorectal, and lung cancer.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
purposeCancer control relies on the identification of populations at risk (hotspots) of new or late-stage cancer diagnoses. However, the extent to which hotspots differ between cancer sites or between outcome measures has been poorly characterized. We sought to determine the geospatial heterogeneity of hotspots of breast, colorectal, and lung cancer incidence and late-stage diagnoses.
methodsWe identified adult patients diagnosed with female breast, colorectal, and lung cancer between 2010 and 2019 in Indiana. To identify hotspots for incidence and late-stage diagnoses, we disaggregated the patient residential location information from the Census block group level to the approximated individual point level. Statistically significant hotspots were identified with kernel ratio estimation. The total areas of hotspots and the overlap between hotspots were compared.
results133,773 patients diagnosed with breast (n = 54,903), colorectal (n = 28,594), and lung (n = 50,276) cancer were included. Geospatial visualization demonstrated marked spatial deviation, with little overlapping area between incidence and late-stage hotspots for all three cancer sites (1-266 km
conclusionsOur results demonstrate considerable geospatial heterogeneity of hotspots between different outcome measures and different sites of cancer. The use of disaggregated spatial data enables a more granular, precise comparison of cancer hotspots. The greatest overlap was seen between incidence hotspots of breast and colorectal cancer, which suggests similar spatial drivers and the potential for coordinated cancer control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.